top of page

Spencer, A., Kalff, A., Shortt, J., et al. A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16). Br J Haematol. 2023; Aug; 202(4):801-811. 

https://doi.org/10.1111/bjh.18955.

View Article

View Supplementary Data

Keywords: KappaMab  |  Phase 2b Clinical Trial  |  Kappa-type multiple myeloma | Lenalidomide | Dexamethasone

Spencer, A., Walker, P., Asvadi, P. et al. A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma. Blood Cancer J. 2019; 9: 58.

https://doi.org/10.1038/s41408-019-0217-5 

View Article

Keywords: KappaMab  |  Clinical Trial  |  Kappa-type multiple myeloma

Asvadi, P., Cuddihy, A., Dunn, R.D., et al. MDX‐1097 induces antibody‐dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015; 169: 333-343. 

https://doi.org/10.1111/bjh.13298

View Article

Keywords: KappaMab  |  In vitro  |  ADCC  |  Free light chains  |  Lenalidomide

Dunn, R.D., Weston, K.M., Longhurst, T.J., et al. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin. Immunotechnology. 1996; 2: 229-40.

View Article

Keywords:   K-1-21 or mKap  

Published Manuscripts

Goodnow, C.C. and Raison, R.L. Structural analysis of the myeloma-associated membrane antigen KMA. J Immunol. 1985; 135(2): 1276-1280.

View Article

Keywords:   KappaMab  |  K-1-21 or mKap  

Walker, K.Z., Boux, H.A., Hayden, G.E., et al. (1985)A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has a potential as a therapeutic agent. In: Microenvironments in the Lymphoid System. Editor: G.G.B Klaus, Plenum Publishing Corporation.

View Article

Keywords:   Free light chains  |  K-1-21 or mKap  

Raison, R.L. and Boux, H.A. Conformation dependence of a monoclonal antibody defined epitope on free human kappa chains. Mol Immunol. 1985; 22(12): 1393-98.

View Article

Keywords:   K-1-21 or mKap  |  Epitope

Boux, H.A., Raison, R.L., Walker, K.Z., et al. The surface expression of a tumor-associated antigen on human kappa myeloma cells. Eur. J Immunol. 1984; 14: 216-222.

View Article

Keywords:   In vitro  |  Free light chains  |  K-1-21 or mKap  |  Epitope

Boux, H.A., Raison, R.L., Walker, K.Z., et al. A  tumour-associated antigen specific for human kappa myeloma cells. J Exp Med. 1983; 158(5): 1769-74.

View Article

Keywords:   In vitro  |  Free light chains  |  K-1-21 or mKap  |  Epitope

Conference Presentations

Dunn, R. Specificity of KMA.CAR T cells against a novel B cell target called kappa myeloma antigen (KMA). IMAPAC - World Asia Biologics Contract Manufacturing Conference, Singapore, 14-15 September 2023

View Presentation

Keywords: KMA | KMA.CAR-T cell | non-clinical data

Sartor, M., Gottlieb, D., and Dunn, R. Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma and in other plasma cell dyscrasias. International Myeloma Society, Athens, Greece, October 2023

View Poster

Keywords: KMA | LMA | Plasma Cell Dyscrasias | KappaMab |10B3 | 7F11 | LambdaMab

Oliaro, J., Li, J., Haynes, N., et al. CAR-T cell therapy targeting kappa myeloma antigen for the treatment of multiple myeloma. International Myeloma Society, Athens, Greece, October 2023

View Poster

Keywords: KMA.CAR T cell | Multiple Myeloma | KMA | Preclinical Research

Sartor, M., Dunn, R., and Gottlieb, D.J.  Kappa myeloma antigen (KMA) and Lambda myeloma antigen (LMA) are expressed on B cell malignancies and are promising novel targets on malignant plasma cells. Hematol Oncol. 2023; 41(S2): 776-777. 

View Abstract

Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | KMA | LMA | Multiple Myeloma

Li J, Haynes N, Cummins K, et al. Cellular Immunotherapy Targeting Kappa Myeloma Antigen for the Treatment of Multiple Myeloma. Cancer Res. 2023; 83 (7_Supplement): 4074.

View Abstract

View Poster

Keywords: Kappa Myeloma Antigen | KMA.CAR T Cells | In Vitro | In Vivo | Multiple Myeloma

Sartor, M., Gottlieb, DJ., and Dunn, R. Novel Antigens LMA and KMA are Expressed on Malignant Bone Marrow Plasma Cells from Patients with Relapsed Refractory Multiple Myeloma and Plasma Cell Dyscrasias. Blood. 2022; 140 (Supplement 1): 4211–4212.

View Abstract

View Poster

View presentation video

Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | Multiple Myeloma | KMA | LMA

Sartor, M., Dunn, R., and Gottlieb, D.J. Expression of kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA) on bone marrow plasma cells in patients with multiple myeloma: implications for antibody and cellular therapy. Myeloma Australia 4th National Myeloma Workshop Event; Pathways to a Cure.  21-23 October 2022. Kalorama, Victoria, Australia.

View Abstract

View Slides

View presentation video

Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | Multiple Myeloma | KMA | LMA

Harrison, S, Li J, Haynes N, et al. Lentiviral generation of CAR-T cells targeting kappa myeloma antigen for the treatment of multiple myeloma. Myeloma Australia 4th National Myeloma Workshop Event; Pathways to a Cure. 21-23 October 2022. Kalorama, Victoria, Australia.

View presentation video

Keywords: Kappa Myeloma Antigen | KMA.CAR T Cells | In Vitro | In Vivo | Multiple Myeloma

Sartor, M., Hu, D., Lemarchand, T.X., et al. A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias. Blood. 2021; 138 (Supplement 1):1595.

View Abstract

View Poster

View presentation video

Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | 10B3 | 7F11

Kalff, A., Shortt, J., Yuen, F., et al. A sequential cohort study comparing KappaMab alone to KappaMab, lenalidomide and low dose dexamethasone in kappa-restricted relapsed refractory (RR) multiple myeloma (AMaRC 01-16). Blood. 2019; 134 (Supplement 1): 3144.

View Abstract

View Poster

Keywords: KappaMab  |  Clinical Trial  |  Kappa-type multiple myeloma  |  Lenalidomide

Gowrishankar, K., Dunn, R., Gottlieb, D., and Micklethwaite, K. CAR T-cells targeting the kappa myeloma antigen for the treatment of multiple myeloma. Cancer Res. 2018; 78 (13_Supplement):3572.

 

View Abstract

View Poster

Keywords:   CAR T cells  |  Kappa-type multiple myeloma

Dunn, R., Spencer, A., Augustson B., et al. Phase 2a, open-label, multi-dose study of the anti-kappa monoclonal antibody, MDX-1097, in relapsed kappa-chain restricted multiple myeloma with stable measurable disease. Haematologica. 2013; 98(s1):776.

 

View Abstract

View Poster

Keywords:   KappaMab / MDX-1097  |  Clinical Trial  |  Kappa-type multiple myeloma KMA

Asvadi, P., Jennings, C., Jiang, V., et al. Identification and characterization of lambda myeloma antigen, LMA, as a therapeutic target in lambda type multiple myeloma. Haematologica. 2013; 98(s1):756.

 

View Poster

Keywords:   Lambda-type multiple myeloma | LMA

Cuddihy, A.R., Khong, T., Dunn, R., et al. The anti-kappa monoclonal antibody MDX-1097 cooperates with lenalidomide to enhance antibody-dependent cell cytotoxicity of multiple myeloma cells.

Cancer Res. 2012; 72 (8_Supplement): 2522. 

View Abstract

View Poster

Keywords:   KappaMab / MDX-1097  |  In vitro  |  ADCC / Apoptosis  |  Lenalidomide

Cuddihy, A.R., Khong, T., Dunn, R., et al. The anti-kappa monoclonal antibody MDX-1097 synergizes with immunomodulatory drugs to enhance antibody-dependent cell cytotoxicity of multiple myeloma cells. Blood. 2012; 120 (21): 4012.

View Abstract

View Poster

Keywords:   KappaMab / MDX-1097  |  In vitro  |  ADCC / Apoptosis

Cuddihy, A. R., Khong, Asvadi, P., et al. HDACi and IMiDs enhance anti-myeloma activity of the anti-KMA monoclonal antibody
MDX-1097. Clin Lymph Myel Leuk. 2013; 13(supplement 1): P-281.
 

View Abstract

View Poster

Keywords: KappaMab | MDX-1097 | ADCC

Spencer, A., Walker, P., Asvadi, P., et al. A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. J  Clin Oncol. 2010; 28(15_suppl):8143.

View Abstract

View Poster

Keywords:   KappaMab / MDX-1097  |  Clinical Trial  |  Kappa-type multiple myeloma / KMA

Wong, M., Asvadi, P., Dunn, R., et al. MDX-1097 Binds specifically to kappa myeloma cells and anti-tumour activity is mediated by multiple effector cells. Blood. 2009; 114(22): 1846.

View Abstract

View Poster

Keywords:   KappaMab / MDX-1097  |  In vitro 

Jones, D.R. Asvadi, P., Raison, R.L., et al. Expression of the kappa myeloma antigen on the cell surface of bone marrow aspirates from Waldenstrom’s Macroglobulinemia patients. Haematologica. 2007; 92(s2): PO-1207.

 

View Abstract

View Poster

Keywords:   KappaMab / MDX-1097  |  In vitro  |  Waldenstrom's macroglobulinemia

Alexova, R., Hutchinson, A., Jones, D.R., et al. Characterisation of a novel conformational epitope on human free kappa light chains defined by a monoclonal antibody with therapeutic potential for multiple myeloma. The Australian and New Zealand Society for Immunology meeting. Sydney Australia, 2007.

View Poster

Keywords:   Free light chains  |  K-1-21 or mKap  |  Epitope

Raison, R.L., Jones, D.R., Asvadi, P., et al. A chimeric monoclonal antibody specific for kappa multiple myeloma plasma cells mediates ADCC of tumor cells. Haematologica. 2005; 90(s1) PO-206.

 

View Abstract

View Poster

Keywords:   K-1-21 or mKap  |  In vivo model

Asvadi, P., Jones, D.R., Dunn, R., et al. A monoclonal antibody specific for free human kappa light chains induces apoptosis of multiple myeloma cells and exhibits anti-tumor activity in vivo. Blood. 2004; 104(11): 2416.
 

View Abstract

View Poster

Keywords:   K-1-21 or mKap  |  In vivo model  |  ADCC / Apoptosis

Published Manuscripts
Poster Presentations

Publications

bottom of page